A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells

We evaluate the application of surfactant-free liquid-phase exfoliated MoS2 nanosheets as a nanoplatform for a cancer detection and treatment system equipped with an antibody–antigen based recognition element. Employing antigen–antibody binding, we increased the probability of the endocytosis of MoS...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials science 2020-04, Vol.8 (7), p.1973-1980
Main Authors: Kálosi, Anna, Labudová, Martina, Annušová, Adriana, Benkovičová, Monika, Bodík, Michal, Kollár, Jozef, Kotlár, Mário, Kasak, Peter, Jergel, Matej, Pastoreková, Silvia, Siffalovic, Peter, Majkova, Eva
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Binding
Biocompatibility
Cancer
Exfoliation
Flow cytometry
Fluorescence
Liquid phases
Molybdenum disulfide
Nanostructure
Toxicity testing
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluate the application of surfactant-free liquid-phase exfoliated MoS2 nanosheets as a nanoplatform for a cancer detection and treatment system equipped with an antibody–antigen based recognition element. Employing antigen–antibody binding, we increased the probability of the endocytosis of MoS2 nanosheets into CAIX expressing cells by 30%. The nanosheets are functionalized with a specific antibody M75, which forms an antigen–antibody complex with CAIX. The bioconjugation of MoS2 nanosheets involves biocompatible components with low cytotoxicity, verified in the tested cell lines by fluorescence-based cell viability assay. The cellular internalization is quantified by flow cytometry, while the internalization is confirmed by label-free confocal Raman imaging. Raman measurements show increased lysosomal activity in the proximity of the internalized nanoplatforms.
ISSN:2047-4830
2047-4849
DOI:10.1039/c9bm01975h